What Are the Different Uses of Atenolol Tablets?
1. The chemical name of this product is: 4- [3-[(1-methylethyl) amino-2-hydroxy] propoxy] phenylacetamide
2. Chemical structural formula:
- Atenolol tablets, the indication is mainly used for the treatment of hypertension, angina pectoris, myocardial infarction, but also for arrhythmia, hyperthyroidism, pheochromocytoma.
- Drug Name
- Atenolol tablets
- Drug type
- Prescription medicines, essential medicines, medicines for medical workers' injuries
- Special medicine
- Doping
- Use classification
- beta receptor blocker
Atenolol tablets ingredients
- 1. The chemical name of this product is: 4- [3-[(1-methylethyl) amino-2-hydroxy] propoxy] phenylacetamide
2. Chemical structural formula:
3. Molecular formula: C 14 H 22 N 2 O 3
4. Molecular weight: 266.34
Atenolol tablet traits
- This product is a white tablet or a sugar-coated tablet, which appears white after removing the sugar coating.
Atenolol Tablet Specifications
- (1) 12.5 mg (2) 25mg
Atenolol tablets dosage
- oral. Usual adult dose: Start 6.25 ~ 12.5mg each time, twice a day, and gradually increase to 50 ~ 200mg as needed and tolerance. When renal function is impaired, creatinine clearance is less than 15ml / (min. 1.73m [sup] 2 [/ sup]), 25mg daily; 15 ~ 35ml / (min. 1.73m [sup] 2 [/ sup]) Up to 50mg daily. Or as directed by your doctor.
Atenolol tablets adverse reactions
- In patients with myocardial infarction, the most common adverse reactions are hypotension and bradycardia; other reactions may include dizziness, cold limbs, fatigue, fatigue, gastrointestinal upset, mental depression, hair loss, thrombocytopenia, psoriasis-like skin reactions, psoriasis Worsening, rash, and dry eyes. Rarely causes cardiac block in sensitive patients.
Atenolol taboo
- 1. - degree cardiac block.
2. Cardiogenic shock.
3. Sick sinus syndrome and severe sinus bradycardia.
Atenolol tablets precautions
- The clinical effect of this product may not be completely parallel to the blood concentration. The dose adjustment shall be based on the clinical effect. The dose should be reduced when renal function is impaired. When patients with heart failure symptoms use this product, digitalis or diuretics are used in combination, such as Symptoms of heart failure still exist, should be gradually reduced; the withdrawal process of this product is at least 3 days, often up to 2 weeks, if there are withdrawal symptoms, such as angina pectoris, temporarily re-administer, and gradually stop after stabilization Coexisting with the diet does not affect its bioavailability; this product can change tachycardia caused by lowering blood sugar; used with caution in hypertensive patients with chronic obstructive pulmonary disease; this drug can cause peripheral arterial blood circulation disorders, Patients may not respond to adrenaline at the usual doses used to treat allergic reactions.
Use with caution by athletes.
Atenolol tablets for pregnant and lactating women
- This product can pass through the placental barrier and appears in the umbilical cord blood. The lack of studies using this drug in the first 3 months does not rule out the possibility of fetal damage. Pregnant women taking this medicine for a long time are related to intrauterine growth retardation. This medicine has a significant agglomeration effect in breast milk, and should be used with caution when lactating women.
Atenolol tablets for children
- It should be used in children from 0.25 to 0.5 mg / kg, twice daily. Pay attention to monitoring heart rate and blood pressure.
Atenolol tablets for the elderly
- The required dose can be reduced, especially in patients with impaired renal function.
Atenolol tablets drug interactions
- Combined with other antihypertensive drugs and diuretics, it can enhance its antihypertensive effect. Special care should be taken with Class I antiarrhythmics, verapamil, and anesthetics. Beta-blockers can aggravate the rebound of hypertension caused by discontinuation of clonidine. If the two drugs are used in combination, this drug should be discontinued a few days before clonidine is discontinued. Beta-blocker therapy is not started until clonidine is stopped for several days.
Atenolol tablets overdose
- For severe bradycardia, 1 to 2 mg of atropine can be injected intravenously. If necessary, a large dose of glucagon 10 mg can be injected intravenously. The response can be repeated or subsequent intravenous drip of glucagon 1 to 10 mg / hour, if not expected. For effect, or without glucagon supply, -receptor agonists can be used.
Atenolol tablets pharmacology and toxicology
- It is a selective 1 adrenergic receptor blocker without membrane stabilization and endogenous sympathomimetic activity. But does not inhibit the bronchiectasis of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce mortality from 0 to 7 days in acute myocardial infarction. The treatment dose did not significantly inhibit myocardial contractility.
Atenolol tablets pharmacokinetics
- Oral absorption is fast, but incomplete. Oral absorption is 50%, reaching peak concentration in 2 to 4 hours. After oral administration, the effect lasts for a long time, up to 24 hours. It is widely distributed in various tissues and can pass through the blood-cerebrospinal fluid barrier in small amounts. . The distribution volume of healthy people is about 50 ~ 75L. The blood drug half-life is 6 to 7 hours. It is mainly excreted from the urine in its original form. When the renal function is impaired, the half-life is prolonged and can be accumulated in the body. This product has low fat solubility, low penetration into brain tissues, and extremely low plasma protein binding rate (6 ~ 16%).
Atenolol tablets storage
- Sealed
Atenolol tablet packaging
- Packed in aluminum-plastic composite film bags, 10 pieces per box x 2 bags. High density polyethylene plastic bottles, 60 tablets per bottle, 50 tablets per bottle.
Atenolol Tablets
- 24 months
Atenolol Tablets
- "Chinese Pharmacopoeia" 2010 edition two